Učitavanje...
5PSQ-026 Efficacy and safety of evolocumab in hypercholesterolaemia and mixed dyslipidaemia
BACKGROUND: The main goal in the therapy of lipids disorders is to prevent morbidity associated with cardiovascular mortality. Evolocumab is a new drug appropiate in reducing the cholesterol level in hypercholesterolaemia and mixed dyslipidaemia. PURPOSE: To describe the efficacy and safety of evolo...
Spremljeno u:
| Izdano u: | Eur J Hosp Pharm |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMJ Group
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535229/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.380 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|